Inhaled aztreonam.
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) - an inhalable formulation of the monobactam antibiotic aztreonam and lysine - was approved by the US FDA to improve respiratory symptoms in patients with cystic fibrosis infected with Pseudomonas aeruginosa.
O'Sullivan
Brian P
BP
Brian P. O'Sullivan is at the University of Massachusetts Memorial Medical Center, 55 Lake Avenue Worcester, Massachusetts 01655, USA. osullivb@ummhc.org
Yasothan
Uma
U
Kirkpatrick
Peter
P
D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001398:Aztreonam / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology; D055808:Drug Discovery; D006801:Humans; D008239:Lysine / Q000737:chemistry; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D001398:Aztreonam; D008239:Lysine